Bioven

Characteristic

Bioven drug is an immunologically active protein fraction (distribution of subclasses of immunoglobulin g in the preparation: igg1 - 52%, igg2 - 32%, igg3 - 7%, igg4 - 4%), the limit content of immunoglobulin a in the preparation is 400 μg / ml.

Bioven Mono is an immunologically active protein fraction (IgG) isolated from human blood plasma, purified and concentrated by ethanol fractionation.

The active component of Bioven / Bioveno mono are antibodies that have specific activity against various pathogens - viruses and bacteria, including hepatitis A and B, cytomegalovirus, herpes simplex virus type I, II and VI, Epstein-Barr virus, chickenpox, influenza, measles, mumps, polio, rubella, pertussis, staphylococcus, E. coli, pneumococcus, tetanus and diphtheria toxin. They also have nonspecific activity, which is manifested by an increase in body resistance.

Bioven has low spontaneous anticomplementary activity.

Bioveno mono lacks anti-complementary properties, since the isolated immunoglobulins are purified from aggregated proteins and impurities.

Bioven is a native immunoglobulin G that retains all biological properties: complement activation, effector and opsonophagocytic functions.

Bioven / Bioveno mono is an immunologically active protein fraction isolated from human serum or plasma, tested for the absence of antibodies to HIV-1, HIV-2, hepatitis C virus and hepatitis B virus surface antigen, purified and concentrated by alcohol fractionation water precipitants, which went through the stage of viral inactivation by the solvent-detergent method.

Data on the effectiveness of inactivation of model viruses are shown in the table below.

The effectiveness of inactivation / elimination of viruses

* PCR - polymerase chain reaction; n / a - no data.

High drug efficacy is ensured by the rapid and 100% entry of antibodies into the bloodstream and normal T_½ out of the body.

After administration, the bioavailability of normal human immunoglobulin in the bloodstream of the recipient is immediate and complete. It is quickly distributed between blood plasma and extravascular fluid, after about 3-5 days a balance is reached between the intra- and extravascular spaces.

T_½ normal human immunoglobulin is about 40 days. This t_½ may vary in each individual patient, especially with primary immunodeficiency. IgG and IgG complexes break down in the cells of the reticuloendothelial system.

P